Rebeccamycin is a microbial metabolite and a well-known topoisomerase I inhibitor. It is used as an antitumor drug.

[1] Pommerehne K, Walisko J, Ebersbach A, et al. The antitumor antibiotic rebeccamycin—challenges and advanced approaches in production processes[J]. Applied microbiology and biotechnology, 2019, 103(9): 3627-3636.

[2] Schwandt A, Mekhail T, Halmos B, et al. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and-II inhibitor, in relapsed “sensitive” small cell lung cancer[J]. Journal of Thoracic Oncology, 2012, 7(4): 751-754.